Is Lakefront Biotherapeutics (GLPGF) a Buy, Sell, or Hold?
OTC : GLPGF
Lakefront Biotherapeutics
$28.08 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 114
- Market Capitalization
- $1.85B
- P/E Ratio
- 3.32
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $48.70
- Year Low
- $22.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $30.48
Company Overview
OTC
Henry Gosebruch
Biotechnology
Healthcare
GLPGF
704
BE
USD
Liquidity Metrics
0.00
30.48
30.30
0.67
0.00
Sales & Valuation
$1.11B
1.54
0.50
-5.33
-4.57
Profitability
$4.87
$320.76M
46.83%
45.14%
16.88%
14.49%
P/E Metrics
3.32
-0.10
-0.10
Analyst Price Target & Rating
4/5
16 Analysts
%
Financial Health Scores
9.97
4/9
$2.97B
$3.39B
$119.51M
$384.03M
Key Metrics (TTM)
$1.56B
1.50
4.75
30.48
16.88%
11.61%
29.93%
-18.56%
$90.77
-1351 days
Company Executives
| Name | Title |
|---|---|
| Jason Treese | Global Head of Quality |
| John W. Mellors | Head of Cell & Antibody Therapy Discovery |
| Fred W. Blakeslee | Executive Vice President & General Counsel |
| Henry Gosebruch | Chief Executive Officer & Executive Director |
| Annelies Missotten | Executive Officer |
| Ellen Van Der Aar | Head of Development |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy |
| Glenn Schulman | Head of Investor Relations |
| Jeevan Shetty | Head of Clinical Development Oncology |
| Tania Philipp | Chief Human Resources Officer |
| Aaron L. Cox | Chief Financial Officer |
| Marieke Vermeersch | Head of Corporation Communication |
Poll Results
No votes yet today — be the first to share your view!
About Lakefront Biotherapeutics (OTC:GLPGF) Stock
Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipeline of investigational drugs, prominently featuring: Filgotinib: A potent JAK1 inhibitor, currently undergoing multiple phases of clinical evaluation for a broad spectrum of inflammatory and autoimmune disorders, such as rheumatoid arthritis, Crohn's disease (including small bowel and fistulizing forms), ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. GLPG1972: This key candidate has successfully completed its Phase 2b trial targeting osteoarthritis. Toledo Molecules: A series of these molecules (GLPG3970, GLPG4399, and GLPG4876) ... are under development with a focus on inflammatory conditions. GLPG4716 and Ziritaxestat: These compounds are being advanced to combat idiopathic pulmonary fibrosis. GLPG2737: Further diversifying the portfolio, this cystic fibrosis transmembrane conductance regulator (CFTR) modulator is currently in Phase 2 clinical trials for patients suffering from autosomal dominant polycystic kidney disease. GLPG0555: Moreover, this other JAK1 inhibitor is progressing through Phase 1b development for the management of osteoarthritis. Galapagos N.V. also maintains strategic collaboration agreements with prominent pharmaceutical partners, including Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG. Established in 1999, the company operates from its headquarters in Mechelen, Belgium.
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
2026-05-07 11:21:21
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Lakefront Biotherapeutics (GLPGF) stock price?
-
Lakefront Biotherapeutics(OTC:GLPGF) stock price is $28.08 in the last trading session. During the trading session, GLPGF stock reached the peak price of $48.7 while $22.39 was the lowest point it dropped to. The percentage change in GLPGF stock occurred in the recent session was 0.0% while the dollar amount for the price change in GLPGF stock was $0.
-
GLPGF's industry and sector of operation?
-
The OTC listed GLPGF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GLPGF?
-
Jason Treese | Global Head of Quality
John W. Mellors | Head of Cell & Antibody Therapy Discovery
Fred W. Blakeslee | Executive Vice President & General Counsel
Henry Gosebruch | Chief Executive Officer & Executive Director
Annelies Missotten | Executive Officer -
How many employees does GLPGF have?
-
Number of GLPGF employees currently stands at 704. GLPGF operates from Generaal De Wittelaan L11 A3, Mechelen, BU 2800, BE.
-
Link for GLPGF official website?
-
Official Website of GLPGF is: https://www.glpg.com
-
How do I contact GLPGF?
-
GLPGF could be contacted at phone #32 1 534 29 00 and can also be accessed through its website. GLPGF operates from Generaal De Wittelaan L11 A3, Mechelen, BU 2800, BE.
-
How many shares of GLPGF are traded daily?
-
The average number of GLPGF shares traded daily for last 3 months was 114.
-
What is the market cap of GLPGF currently?
-
The market value of GLPGF currently stands at $1.85B with its latest stock price at $28.08